Frecuencia de úlceras digitales en esclerodermia
Resumen
Nuestro objetivo fue describir la frecuencia de úlceras digitales en una población de pacientes con Esclerosis Sistémica y comparar las características clínicas de los que desarrollaron úlceras de los que no lo hicieron. Se incluyeron en forma retrospectiva pacientes que cumplían criterios ACR para Esclerosis Sistémica. Se recolectaron datos demográficos, clínicos y serológicos de las historias clínicas. Se clasificó a los pacientes en dos grupos: un Grupo A con úlceras digitales y Grupo B aquellos pacientes sin antecedentes de úlceras digitales. Se compararon ambos grupos. Se estudiaron 60 pacientes con diagnóstico de Esclerosis Sistémica, 33% subtipo difuso, edad promedio al diagnóstico de 50,75 ± 14,75 años, el 15% (9 pacientes) eran de sexo masculino.Citas
I. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, Montagna G et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;81:139–53.
II. Ingraham KM, Steen VD. Morbidity of digital tip ulcerations in scleroderma. Arthritis Rheum 2006; 54(9):P578.
III. Nihtyanova S et al. Clinical burden of digital vasculo-pathy in limited and diffuse cutaneous systemic scle-rosis. Ann Rheum Dis 2008;67:120-123.
IV. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
V. Matucci-Cerinic M, Denton CP, Fust DE et al. Bo-sentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomized, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan; 70(1):32-8.
VI. Matucci-Cerinic M, Seibold JR. Digital ulcers and out-comes assessment in scleroderma. Rheum 2008;47:46-47.
VII. Sebastiani M, Manfredi A, Vukatana G et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: A multicenter validation study. Ann Rheum Dis 2012; 71(1):67-70.
VIII. Harrison et al. Cigarette smoking as a significant risk factor for digital vascular disease in patients with sys-temic sclerosis. Arthritis Rheum 2002;46:3312-6.
IX. Black C, Denton CP, Furst DE et al. Bosentan reduces the number of new digital ulcers in patients with sys-temic sclerosis – open label extension to a double-blind trial. Ann Rheum Dis 2006;65(II):384.
X. Subcommittee for Scleroderma Criteria of the Ameri-can Rheumatism Association Diagnostic and Thera-peutic Criteria Committee: Preliminary Criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23:581-90.
XI. Cutolo M et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheum 2004;43:719-26.
XII. Mouthon L et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010;69:214-217.
XIII. Caramaschi P et al. Digital amputation in systemic scle-rosis: Prevalence and clinical associations. A retrospec-tive Longitudinal Study. Journal of Rheumatol 2012; 39:1648-1653.
XIV. Khimdas et al. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group Registry. Arthritis Care & Research 2011;63:142-149.
XV. Steen V et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheum 2009;48:19-24.
XVI. Meier M et al, EUSTAR Co-authors. Update on the profile of the EUSTAR cohort: an analysis of the EU-LAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012; 17:1355-1360.
XVII. Ostojic P et al. Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and dif-fuse subset of disease. Clin Hemorheol Microcirc 2004;31:281-5
Derechos de autor 2016 Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
